Peptides Similar to Teriparatide
Compare Teriparatide with related peptides and alternatives
📌TL;DR
- •1 similar peptides identified
- •Abaloparatide: Very High - Both are PTH1 receptor agonist peptides approved for osteoporosis, administered as daily subcutaneous injections
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Teriparatide (current) | - | - |
| Abaloparatide | Very High - Both are PTH1 receptor agonist peptides approved for osteoporosis, administered as daily subcutaneous injections | Teriparatide is native PTH(1-34) with balanced RG/R0 binding, while abaloparatide is a PTHrP analog with RG-selective binding. Teriparatide has broader indications (including GIO) and longer market experience. |
Peptides Related to Teriparatide#
Teriparatide is the founding member of the osteoanabolic therapeutic class. As the first 34 amino acids of native human parathyroid hormone, it set the standard for bone-forming therapy and remains the most extensively studied osteoanabolic agent. The key comparison is with abaloparatide (PTHrP analog), with romosozumab (anti-sclerostin antibody) representing an alternative osteoanabolic mechanism.
Abaloparatide (Tymlos)#
Abaloparatide is a 34-amino-acid synthetic analog of PTHrP developed by Radius Health (Ipsen), approved as Tymlos in 2017 for postmenopausal osteoporosis and expanded to men in 2023.
Mechanism comparison: Both agents activate PTH1R. Teriparatide binds both the RG and R0 receptor conformations, producing more prolonged cAMP signaling. Abaloparatide preferentially binds RG, producing more transient signals. This difference explains abaloparatide's lower hypercalcemia rates and potentially greater cortical bone specificity.
Clinical efficacy -- ACTIVE trial: The ACTIVE trial compared abaloparatide 80 mcg versus open-label teriparatide 20 mcg daily:
| Endpoint | Teriparatide | Abaloparatide |
|---|---|---|
| Lumbar spine BMD | +10.5% | +9.2% |
| Total hip BMD | +2.0% | +2.9% (P<0.05) |
| Femoral neck BMD | +2.7% | +3.4% |
| Hypercalcemia | 6.4% | 3.4% |
| ISR rate | 7% | 16% |
Indications and experience: Teriparatide has broader approved indications (including glucocorticoid-induced osteoporosis) and over 20 years of market experience. Its osteosarcoma boxed warning was removed in 2020, eliminating the 2-year treatment limit. Biosimilar availability has improved cost accessibility.
Key trade-off: Teriparatide offers broader indications, longer safety track record, no treatment duration limit, and biosimilar availability. Abaloparatide offers superior hip BMD, lower hypercalcemia, and room-temperature storage after first use.
| Parameter | Teriparatide | Abaloparatide |
|---|---|---|
| Parent peptide | PTH(1-34) | PTHrP(1-34) analog |
| Receptor binding | RG + R0 | RG-preferring |
| FDA approval | 2002 | 2017 |
| Indications | PMO, male OP, GIO | PMO, male OP |
| Duration limit | None (removed 2020) | Up to 2 years |
| Hypercalcemia | 11% | 3.4% |
| Storage | Continuous refrigeration | Room temp after first use |
| Biosimilars | Available | Not available |
Romosozumab (Evenity)#
Romosozumab is a humanized monoclonal antibody against sclerostin, approved in 2019 for postmenopausal osteoporosis at high fracture risk.
Mechanism comparison: While teriparatide activates PTH1R on osteoblasts, romosozumab inhibits sclerostin to simultaneously stimulate bone formation and reduce bone resorption. This dual-action mechanism produces more rapid and greater BMD gains.
Clinical efficacy: Romosozumab produces larger BMD gains at 12 months (lumbar spine +13%) compared to teriparatide at equivalent timepoints. The ARCH trial demonstrated that romosozumab followed by alendronate was superior to alendronate alone for fracture reduction.
Safety: Romosozumab carries a boxed warning for cardiovascular events (MI, stroke) not present with teriparatide. It is contraindicated in patients with recent MI or stroke.
Key trade-off: Romosozumab offers faster and larger BMD gains with monthly dosing but carries cardiovascular risk. Teriparatide has no cardiovascular concern, broader indications, and 20+ years of safety data.
Summary Comparison#
| Feature | Teriparatide | Abaloparatide | Romosozumab |
|---|---|---|---|
| Drug class | PTH(1-34) | PTHrP analog | Anti-sclerostin mAb |
| Dosing | SC daily | SC daily | SC monthly |
| Duration | No limit | Up to 2 years | 12 months |
| Indications | PMO, male OP, GIO | PMO, male OP | PMO |
| Lumbar spine BMD | +9-10% (18 mo) | +9.2% (18 mo) | +13% (12 mo) |
| Key safety | Hypercalcemia | ISR, mild hypercalcemia | CV events |
| Market since | 2002 | 2017 | 2019 |
| Biosimilars | Yes | No | No |
Related Reading#
Frequently Asked Questions About Teriparatide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer